Cerevel Therapeutics Reports Results from P-III Adjunctive Study Evaluating Tavapadon for the Treatment of Advanced Parkinson’s Disease
Shots:
- Cerevel reports results from the TEMPO-3, a P-III study (n= 507; 40-80yrs.), evaluating the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy levodopa (LD) (titrated to 5-15mg) in adult patients, vs PBO and LD, orally and QD
- Study (>27wks.) met 1EP, showing an increase of 1.1 hours in total “on” time from baseline without affecting dyskinesia vs LD + PBO (1.7 hrs. vs 0.6 hrs., p<0.0001); also met key 2EP, a substantial reduction in “off” time from baseline (MDS-UPDRS Part I, II, and III scores)
- Furthermore, Cerevel is conducting a fourth OLE study (TEMPO-4) to assess the long-term safety and tolerability of tavapadon and results from P-III monotx. (TEMPO-1 & TEMPO-2) study is expected in H2`24
Ref: Cerevel | Image: Cerevel
Related News:- AbbVie to Acquire Cerevel Therapeutics for ~$8.7B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
